Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
1.880
-0.110 (-5.53%)
At close: Nov 13, 2026, 4:00 PM EST
1.875
-0.005 (-0.27%)
After-hours: Nov 13, 2026, 7:30 PM EST
Fortress Biotech Revenue
Fortress Biotech had revenue of $19.16M in the quarter ending September 30, 2026, with 8.67% growth. This brings the company's total for the last twelve months to $69.99M, up 12.34% year-over-year. In the year 2025, Fortress Biotech had annual revenue of $63.26M with 9.69% growth. That makes Fortress Biotech the 25,467th largest company in the world by revenue and 3,539th in the United States.
Revenue (ttm)
$69.99M
Revenue Growth
+12.34%
P/S Ratio
0.90
Revenue / Employee
$897,346
Employees
78
Market Cap
62.70M
Revenue by Segment
- Journey 61.86M 97.8%
- Avenue 1.40M 2.2%
Fiscal year ended Dec 31, 2025 See the full Fortress Biotech breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.26M | 5.59M | 9.69% |
| Dec 31, 2024 | 57.68M | -26.84M | -31.76% |
| Dec 31, 2023 | 84.51M | 8.77M | 11.58% |
| Dec 31, 2022 | 75.74M | 6.95M | 10.11% |
| Dec 31, 2021 | 68.79M | 23.19M | 50.86% |
| Dec 31, 2020 | 45.60M | 8.97M | 24.49% |
| Dec 31, 2019 | 36.63M | 9.75M | 36.26% |
| Dec 31, 2018 | 26.88M | 9.64M | 55.88% |
| Dec 31, 2017 | 17.25M | 11.09M | 180.09% |
| Dec 31, 2016 | 6.16M | 5.29M | 613.44% |
| Dec 31, 2015 | 863.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 148.22M |
| Gossamer Bio | 78.42M |
| Champions Oncology | 60.66M |
| Tonix Pharmaceuticals Holding | 43.05M |
| Verrica Pharmaceuticals | 30.32M |
FBIO News
- 2 days ago - Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 2 days ago - Fortress Biotech Earnings Call Transcript: Q3 2026 - Transcripts
- 2 days ago - Fortress Biotech Earnings release: Q3 2026 - Filings
- 2 days ago - Fortress Biotech Quarterly report: Q3 2026 - Filings
- 2 days ago - Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 4 days ago - Fortress Biotech unit licenses FB-607 from Cedars-Sinai - TheFly
- 4 days ago - Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) - GlobeNewsWire
- 10 days ago - Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026 - GlobeNewsWire